VRTX241227C410000
- 2.40
- +0.35+17.07%
Vertex Pharmaceuticals Newsroom
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $460
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $430 to $525
RBC Capital Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Price Target Raised to $430.00/Share From $426.00 by Scotiabank
Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
TD Cowen Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $500
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Vertex Pharmaceuticals (VRTX) and Ascendis Pharma (ASND)
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $418
J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $500
JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $500 From $503, Keeps Overweight Rating
Scotiabank Adjusts Price Target on Vertex Pharmaceuticals to $430 From $426, Keeps Sector Perform Rating
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $418 to $535
Barclays Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals: Buy Rating Despite LSR Trial Setback, Future Prospects Remain Strong
Redburn Atlantic Adjusts Vertex Pharmaceuticals Price Target to $550 From $570, Maintains Buy Rating
Bernstein Adjusts Vertex Pharmaceuticals Price Target to $441 From $506, Maintains Market Perform Rating
Barclays Adjusts Vertex Pharmaceuticals Price Target to $418 From $509, Maintains Equalweight Rating